Search Results - "van den Neste, Eric"

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients by Donadieu, Jean, Lamant, Marie, Fieschi, Claire, de Fontbrune, Flore Sicre, Caye, Aurélie, Ouachee, Marie, Beaupain, Blandine, Bustamante, Jacinta, Poirel, Hélène A, Isidor, Bertrand, Van Den Neste, Eric, Neel, Antoine, Nimubona, Stanislas, Toutain, Fabienne, Barlogis, Vincent, Schleinitz, Nicolas, Leblanc, Thierry, Rohrlich, Pierre, Suarez, Felipe, Ranta, Dana, Chahla, Wadih Abou, Bruno, Bénédicte, Terriou, Louis, Francois, Sylvie, Lioure, Bruno, Ahle, Guido, Bachelerie, Françoise, Preudhomme, Claude, Delabesse, Eric, Cave, Hélène, Bellanné-Chantelot, Christine, Pasquet, Marlène

“…Heterozygous germline mutations strongly predispose to leukemia, immunodeficiency, and/or lymphoedema. We describe a series of 79 patients (53 families)…”
Get full text

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial by Wulf, Gerald G., Altmann, Bettina, Ziepert, Marita, D’Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M., Neste, Eric Van Den, Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Gelder, Michel van, van Imhoff, Gustaaf W., Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz

“…PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in…”
Get full text

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial by DEMEESTERE, Isabelle, BRICE, Pauline, BRON, Dominique, ENGLERT, Yvon, PECCATORI, Fedro A, KENTOS, Alain, GAILLARD, Isabelle, ZACHEE, Pierre, CASASNOVAS, Rene-Olivier, VAN DEN NESTE, Eric, DECHENE, Julie, DE MAERTELAER, Vivianne

“…To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or…”
Get full text

Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants by TROTMAN, Judith, FOURNIER, Marion, FORSYTH, Cecily, DECAUDIN, Didier, FABIANI, Bettina, GABARRE, Jean, SALLES, Bruno, DEN NESTE, Eric Van, CANIONI, Danielle, GARIN, Etienne, FULHAM, Michael, BORGHT, Thierry Vander, LAMY, Thierry, SALLES, Gilles, SEYMOUR, John Francis, SONET, Anne, JANIKOVA, Andrea, SHPILBERG, Ofer, GYAN, Emmanuel, TILLY, Hervé, ESTELL, Jane

“…The utility of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy…”
Get full text

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia by Stilgenbauer, Stephan, Aurran Schleinitz, Thérèse, Eichhorst, Barbara, Lang, Fabian, Offner, Fritz, Rossi, Jean-François, Schroyens, Wilfried, Van Den Neste, Eric, Ysebaert, Loïc, von Wangenheim, Ute, Ursula Kress, Uta, Blum, Petra, Zenz, Thorsten

Get full text

Effect of N‐acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial by Sins, Joep W. R., Fijnvandraat, Karin, Rijneveld, Anita W., Boom, Martine B., Kerkhoffs, Jean‐Louis H., Meurs, Alfred H., Groot, Marco R., Heijboer, Harriët, Dresse, Marie‐Françoise, Lê, Phu Quoc, Hermans, Philippe, Vanderfaeillie, Anna, Van Den Neste, Eric W., Benghiat, Fleur S., Kesse‐Adu, Rachel, Delannoy, André, Efira, André, Azerad, Marie‐Agnès, Borgie, Corianne A., Biemond, Bart J.

Get full text

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study by Crump, Michael, Neelapu, Sattva S., Farooq, Umar, Van Den Neste, Eric, Kuruvilla, John, Westin, Jason, Link, Brian K., Hay, Annette, Cerhan, James R., Zhu, Liting, Boussetta, Sami, Feng, Lei, Maurer, Matthew J., Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian

“…Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from…”
Get full text

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial by Trappe, Ralf U, Dierickx, Daan, Zimmermann, Heiner, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M, Dreyling, Martin H, Dührsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Hüttmann, Andreas, Tousseyn, Thomas, Salles, Gilles, Kliem, Volker, Hauser, Ingeborg A, Tarella, Corrado, Van Den Neste, Eric, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno, Choquet, Sylvain

“…Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548)…”
Get full text

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma by Le Gouill, Steven, Thieblemont, Catherine, Oberic, Lucie, Moreau, Anne, Bouabdallah, Krimo, Dartigeas, Caroline, Damaj, Gandhi, Gastinne, Thomas, Ribrag, Vincent, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Haioun, Corinne, Maisonneuve, Hervé, Houot, Roch, Jardin, Fabrice, Van Den Neste, Eric, Tournilhac, Olivier, Le Dû, Katell, Morschhauser, Franck, Cartron, Guillaume, Fornecker, Luc-Matthieu, Canioni, Danielle, Callanan, Mary, Béné, Marie C, Salles, Gilles, Tilly, Hervé, Lamy, Thierry, Gressin, Remy, Hermine, Olivier

“…The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall…”
Get full text

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte by Coiffier, Bertrand, Thieblemont, Catherine, Van Den Neste, Eric, Lepeu, Gérard, Plantier, Isabelle, Castaigne, Sylvie, Lefort, Sophie, Marit, Gérald, Macro, Margaret, Sebban, Catherine, Belhadj, Karim, Bordessoule, Dominique, Fermé, Christophe, Tilly, Hervé

“…We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab…”
Get full text

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study by Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, Morschhauser, Franck

“…Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple…”
Get full text

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier by Carpio, Cecilia, Bouabdallah, Reda, Ysebaert, Loïc, Sancho, Juan-Manuel, Salles, Gilles, Cordoba, Raul, Pinto, Antonio, Gharibo, Mecide, Rasco, Drew, Panizo, Carlos, Lopez-Martin, Jose A., Santoro, Armando, Salar, Antonio, Damian, Silvia, Martin, Alejandro, Verhoef, Gregor, Van den Neste, Eric, Wang, Maria, Couto, Suzana, Carrancio, Soraya, Weng, Andrew, Wang, Xuehai, Schmitz, Frank, Wei, Xin, Hege, Kristen, Trotter, Matthew W.B., Risueño, Alberto, Buchholz, Tonia J., Hagner, Patrick R., Gandhi, Anita K., Pourdehnad, Michael, Ribrag, Vincent

“…Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to…”
Get full text

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia by Herbaux, Charles, Kornauth, Christoph, Poulain, Stéphanie, Chong, Stephen J.F., Collins, Mary C., Valentin, Rebecca, Hackett, Liam, Tournilhac, Olivier, Lemonnier, François, Dupuis, Jehan, Daniel, Adrien, Tomowiak, Cecile, Laribi, Kamel, Renaud, Loïc, Roos-Weil, Damien, Rossi, Cedric, Van Den Neste, Eric, Leyronnas, Cecile, Merabet, Fatiha, Malfuson, Jean Valère, Tiab, Mourad, Ysebaert, Loïc, Ng, Samuel, Morschhauser, Franck, Staber, Philipp B., Davids, Matthew S.

“…Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and…”
Get full text

Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study) by Nguyen‐Khac, Florence, Baron, Marine, Guièze, Romain, Feugier, Pierre, Fayault, Alexandra, Raynaud, Sophie, Troussard, Xavier, Droin, Nathalie, Damm, Frederik, Smagghe, Luce, Susin, Santos, Leblond, Véronique, Dartigeas, Caroline, Van den Neste, Eric, Leprêtre, Stéphane, Bernard, Olivier A., Roos‐Weil, Damien

“…Summary The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the…”
Get full text

microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification by Stamatopoulos, Basile, Meuleman, Nathalie, Haibe-Kains, Benjamin, Saussoy, Pascale, Van Den Neste, Eric, Michaux, Lucienne, Heimann, Pierre, Martiat, Philippe, Bron, Dominique, Lagneaux, Laurence

“…Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by…”
Get full text

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial by Lepretre, Stephane, Aurran, Therese, Mahé, Beatrice, Cazin, Bruno, Tournilhac, Olivier, Maisonneuve, Herve, Casasnovas, Olivier, Delmer, Alain, Leblond, Veronique, Royer, Bruno, Corront, Bernadette, Chevret, Sylvie, Delépine, Roselyne, Vaudaux, Sandrine, Van Den Neste, Eric, Béné, Marie Christine, Letestu, Remi, Cymbalista, Florence, Feugier, Pierre

“…A French and Belgian multicenter phase 3 trial was conducted in medically fit patients with untreated chronic lymphocytic leukemia. Of 178 patients enrolled in…”
Get full text

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma by Van Den Neste, Eric, André, Marc, Gastinne, Thomas, Stamatoullas, Aspasia, Haioun, Corinne, Belhabri, Amine, Reman, Oumedaly, Casasnovas, Olivier, Ghesquieres, Hervé, Verhoef, Gregor, Claessen, Marie-José, Poirel, Hélène A, Copin, Marie-Christine, Dubois, Romain, Vandenberghe, Peter, Stoian, Ioanna-Andrea, Cottereau, Anne S, Bailly, Sarah, Knoops, Laurent, Morschhauser, Franck

“…JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing…”
Get full text

Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial by Tessoulin, Benoit, Chiron, David, Thieblemont, Catherine, Oberic, Lucie, Bouadballah, Kamal, Gyan, Emmanuel, Damaj, Gandhi, Ribrag, Vincent, Gressin, Rémy, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Lemonnier, François, Maisonneuve, Hervé, Joubert, Clementine, Van Den Neste, Eric, Lamy, Thierry, Tilly, Hervé, Moreau, Anne, Hermine, Olivier, Le Gouill, Steven

“…LyMA trial has demonstrated the benefit of rituximab maintenance after autologous stem cell transplantation (ASCT) in previously untreated mantle-cell lymphoma…”
Get full text

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma by Le Gouill, Steven, Thieblemont, Catherine, Oberic, Lucie, Moreau, Anne, Bouabdallah, Krimo, Dartigeas, Caroline, Damaj, Gandhi, Gastinne, Thomas, Ribrag, Vincent, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Haioun, Corinne, Maisonneuve, Hervé, Houot, Roch, Jardin, Fabrice, Van Den Neste, Eric, Tournilhac, Olivier, Le Dû, Katell, Morschhauser, Franck, Cartron, Guillaume, Fornecker, Luc-Matthieu, Canioni, Danielle, Callanan, Mary, Béné, Marie C., Salles, Gilles, Tilly, Hervé, Lamy, Thierry, Gressin, Remy, Hermine, Olivier

Get full text

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes by Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., Goy, Andre

“…The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of…”
Get full text